Neurocrine Biosciences

NBIX

Market cap $13.2B

Investors need to pay close attention to NBIX stock based on the movements in the options market latel.

Conference Call and Webcast Scheduled for Tuesday, May 5 SAN DIEGO, April 14, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its first quarter 2026 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m.

INGREZZA showed higher rates of long-term treatment continuation and lower switching between medications compared to AUSTEDO XR (deutetrabenazine) in a real-world claims analysis among adults with tardive dyskinesia Higher continuation with INGREZZA was observed early in treatment and persisted across a six‑month follow‑up period SAN DIEGO, April 14, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new real-world evidence demonstrating that adult patients with tardive dyskinesia receiving INGREZZA® (valbenazine) capsules showed higher treatment persistence compared to those on AUSTEDO XR (deutetrabenazine). The findings are being presented at the Academy of Managed Care Pharmacy 2026 Annual Meeting in Nashville.

Tokyo, Japan and Cambridge, UK, 13 April 202 6 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that its partner Neurocrine Biosciences Inc. (“Neurocrine”) has initiated and dosed the first patient(s) in a Phase 2 clinical study of NBI-1117570 (“NBI-'570”) in adults with schizophrenia. As a result, Nxera will receive milestone payments of US$22.5 million from Neurocrine pursuant to the agreement. The milestone payments will be recognised as revenue in Q1 FY2026. NBI-‘570 is an investigational, orally administered, dual muscarinic M1/M4 receptor agonist discovered using Nxera's proprietary NxWave™ drug discovery platform.

Soleno Therapeutics said on Tuesday it has voluntarily withdrawn the European marketing application for its ​rare metabolic disorder drug following acquirer Neurocrine's ‌plans to sharpen focus on the U.S. market.

Neurocrine Biosciences, Inc. (NBIX) M&A Call Transcript

Neurocrine Biosciences (NASDAQ:NBIX) has agreed to acquire Soleno Therapeutics (NASDAQ:SLNO) in an all-cash transaction valued at approximately $2.9 billion, it was announced on Monday. Under the terms of the agreement, Neurocrine will pay $53 per share for Soleno, representing a premium of about 34% over Soleno's closing stock price on April 2, 2026, and roughly 51% above its 30-day average.

Neurocrine Biosciences agreed to buy Soleno Therapeutics for $2.9 billion in a move intended to expand its endocrinology and rare-disease portfolio.

Neurocrine Biosciences stock fell after the merger was announced.

PepsiCo (PEP) drops sponsorship of a major London music festival after controversy over Kanye West as headliner. Anthropic is being courted by the UK for a London expansion and potential dual listing, amid ongoing legal issues with the US government.